VERRICA PHARMACEUTICALS INC. - COMMON STOCK

Verrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference

07 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

05 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results

02 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference

24 Feb 2022 07:30:01 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum

15 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

29 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma

18 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results

12 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

20 Sep 2021 16:05:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results

10 Aug 2021 07:30:01 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

09 Jul 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

28 May 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference

26 May 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

12 May 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results

07 May 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

06 Apr 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association

29 Mar 2021 07:30:00 By Nasdaq GlobeNewswire

Verrica Announces Pricing of Public Offering of Common Stock

22 Mar 2021 21:31:20 By Nasdaq GlobeNewswire

Verrica Announces Proposed Public Offering of Common Stock

22 Mar 2021 16:01:20 By Nasdaq GlobeNewswire

Verrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan

17 Mar 2021 07:00:00 By Nasdaq GlobeNewswire